Theriva Biologics, Inc.
TOVX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | -0.00 | 0.82 |
| FCF Yield | -717.95% | -277.31% | -275.40% | -1.56% |
| EV / EBITDA | 0.30 | 0.71 | 1.73 | -53.82 |
| Quality | ||||
| ROIC | -66.02% | -40.12% | -30.93% | -21.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 1.04 | 0.97 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 11.77% | 0.00% | -48.78% | -5.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 1.06 | 2.09 | 4.64 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,288.58 | -2,081.85 | -1,246.18 | -2,198.39 |